That small detail is going to be left to a 100-strong panel of random Brits, chosen to represent a cross-section of the population. They will decide which aspects of public life are most in need of ...

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with relapsing forms of ...

A blending of committed youth groups from Fayette County gathered at the Summit Bechtel Reserve last weekend for a special ...

Preview this article 1 min If the company moves forward with the project on a 186-acre site, it could entail more than $1 billion in investment in a growing area of Fort Worth. Get the latest in this ...

Taking a closer look at how employability skills are developed is helping employers and university staff narrow the long‑standing gap between classroom theory and workplace reality in San Antonio.

About Upbound Group, Inc. Upbound Group, Inc. (NASDAQ: UPBD), is a technology and data-driven leader in accessible and inclusive financial solutions that address the evolving needs and aspirations of ...

The third-grade students in Morgan Singleton’s class at Emerson Elementary School recently completed a unit about newspapers, ...

Abstract: Accurately selecting the proper data presentation tool based on the type of data being used is one of the most essential steps toward developing a robust and effective data communication ...

I'm your downtown Lansing neighborhood reporter. I strive to tell the real and honest stories of this great community, and I will work tirelessly to provide you with the truth. LANSING, Mich — The ...

NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (TGTX), today announced the presentation of data highlighting BRIUMVI ® (ublituximab-xiiy), to be presented at the Americas Committee ...

All CSS classes, callouts, and slide options work the same way — only the format string changed. Both themes share a 700+ line layout partial (_shared.scss) providing consistent slide components ...

Hunter syndrome (MPS II) presentations will include analysis from continued follow-up of Phase 1/2 data for tividenofusp alfa (DNL310), currently under FDA Priority Review Preliminary data from Phase ...